The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Yue Pan, Yucheng Fu, Yue Zeng, Xiaohan Liu, Yurong Peng, Chunhong Hu, Chao Deng, Zhenhua Qiu, Jian Zou, Yuxuan Liu, Fang Wu
Abstract
Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although these indicators have a certain predictive effect, their predictive performance is not good. Therefore, clinicians must make adjustments to recognize markers. This is a review article that summarized immunotherapeutic biomarkers according to the "seed-soil-environment", generalizes primary resistance to immunotherapy, and summarizes the integration of markers.